Introduction of compounds expected to be developed as new NASH treatments.
At Renac Therapeutics, we handle "Pharmaceutical Pipeline NASH Therapeutics (Nucleic Acid Medicines)." Using our proprietary technology, Hetero Double-Stranded Nucleic Acid (HDO) technology, we have discovered compounds that inhibit the expression of the NASH-related gene IHH. These compounds are expected to improve the NAFLD activity score in NASH animal models by inhibiting IHH expression, paving the way for the development of a novel NASH therapeutic. [Features] - Effectively inhibits the expression of the NASH-related gene IHH. - Also suppresses the expression of fibrosis marker genes such as COL1A1, CTGF, and TIMP1, suggesting potential as a fibrosis treatment. *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Renac Therapeutics Co., Ltd. aims to create new nucleic acid drugs through a platform-based business model. Instead of a business model that derives profits by licensing out drugs developed through in-house research to pharmaceutical companies (the so-called pipeline model), we are developing a business model that collaborates with pharmaceutical companies from the drug discovery research stage and jointly develops drugs with them.